S-ICD® System IDE Clinical Study
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||S-ICD® System Clinical Investigation|
- Percentage of Participants Free of Type I Complications at 180 Days. [ Time Frame: 180 days ]Percentage of Participants Free of Type I Complications at 180 days compared to the performance goal of 79%. Type I complications are those caused by the S-ICD System.
- Percentage of Participants Who Pass Induced VF Conversion Test [ Time Frame: Implant/Pre-Discharge ]Percentage of participants who pass induced VF conversion test was compared to a performance goal of 88%. Definition of a success was two consecutive successful 65 joule shocks out of four attempts in the same polarity.
|Study Start Date:||January 2010|
|Study Completion Date:||January 2013|
|Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
Experimental: S-ICD System
This is a single arm study
Device: S-ICD System
The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
This clinical study is a prospective, non-randomized, multicenter clinical study without a control group conducted in the United States, Europe, and New Zealand.
Patients meeting eligibility criteria for implanting an S-ICD System will be enrolled in this clinical study, implanted with an S-ICD System, and followed prior to hospital discharge, and post-implant at 30 days, 90 days, and 180 days. After the 180-day post-implant follow-up visit, patients will continue to be followed semi-annually until study closure.
Eligible patients enrolled in this clinical study may also participate in the chronic conversion sub-study.
The safety endpoint will be evaluated through the use of a 180-day S-ICD System complication-free rate. The effectiveness endpoint will be evaluated using an induced ventricular fibrillation (VF) conversion efficacy rate. Spontaneous episodes and chronic conversion testing data will be evaluated using descriptive statistics to provide additional data supporting the continued chronic performance of the S-ICD System.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01064076
Show 33 Study Locations
|Study Director:||Michael Husby, M.S., MPH||Cameron Health, Inc. a Subsidiary of Boston Scientific|